CoChat

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily

Open access
Meneghini, Luigi, Atkin, Stephen L., Gough, Stephen C.L., Raz, Itamar, Blonde, Lawrence, Shestakova, Marina, Bain, Stephen, Johansen, Thue, Begtrup, Kamilla, Birkeland, Kåre I., on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators · 2013 · Diabetes Care

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin. RESEARCH DESIGN AND METHODS: This 26-week, open-label, treat-to-target trial enrolled adults (≥18 years) with type 2 diabetes who were either insulin naïve and receiving oral antidiabetic drugs (OADs) (HbA1c = 7–11%) or previously on basal insulin ± OAD(s) (HbA1c = 7–10%). Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8–40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230). The primary outcome was noninferiority of IDeg OD Flex to IGlar OD in HbA1c reduction after 26 weeks. RESULTS: After 26 weeks, IDeg OD Flex, IDeg OD, and IGlar OD improved HbA1c by 1.28, 1.07, and 1.26% points, respectively (estimated treatment difference [IDeg OD Flex − IGlar OD]: 0.04% points [–0.12 to 0.20], confirming noninferiority). No statistically significant differences in overall or nocturnal hypoglycemia were found between IDeg OD Flex and IGlar OD. Comparable glycemic control and rates of hypoglycemia were seen with IDeg OD Flex and IDeg OD. Adverse event profiles were similar across groups. CONCLUSIONS: The use of extreme dosing intervals of 8–40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-1668

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Dosing schedule for IDeg OD Flex treatment group. *, defined as the period from waking up until first meal of the day; †, defined as the period from start of evening meal until bedtime. A 24-h interval was introduced between Saturday and Sunday evening doses to ensure an equal number of short (8–12 h) and long (36–40 h) intervals during the week.
Figure 1 Dosing schedule for IDeg OD Flex treatment group. *, defined as the period from waking up until first meal of the day; †, defined as the period from start of evening meal until bedtime. A 24-h interval was introduced between Saturday and Sunday evening doses to ensure an equal number of short (8–12 h) and long (36–40 h) intervals during the week.CC BY-NC-ND · PubMed Central
Figure 2 Glycemic efficacy and cumulative nocturnal hypoglycemia. A: Mean HbA1c (±SEM) over time. B: Mean FPG (±SEM) over time. C: Mean 9-point SMPG profiles at baseline (dashed lines) and week 26 (full lines). D: Cumulative mean number of nocturnal hypoglycemic episodes per participant. For A and B, data are observed mean values for all randomized participants (last observation carried forward is used for each postbaseline time point). Plasma-calibrated values are shown in C. Nocturnal confirmed hypoglycemia, confirmed hypoglycemia with an onset between 00:01 h and 05:59 h (inclusive).
Figure 2 Glycemic efficacy and cumulative nocturnal hypoglycemia. A: Mean HbA1c (±SEM) over time. B: Mean FPG (±SEM) over time. C: Mean 9-point SMPG profiles at baseline (dashed lines) and week 26 (full lines). D: Cumulative mean number of nocturnal hypoglycemic episodes per participant. For A and B, data are observed mean values for all randomized participants (last observation carried forward is used for each postbaseline time point). Plasma-calibrated values are shown in C. Nocturnal confirmed hypoglycemia, confirmed hypoglycemia with an onset between 00:01 h and 05:59 h (inclusive).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. International Diabetes Federation, 2011, Diabetes Atlas
  2. Heise, 2011, Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (Abstract), Diabetologia, 54, S425
  3. Kurtzhals, 2011, Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec (Abstract), Diabetologia, 54, S426

Cited by

See all 226

Metadata

Authors
Meneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., & on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators
Affiliations
  • University of Miami (US)
  • Hull York Medical School (GB)
  • Churchill Hospital (GB)
  • Hadassah Medical Center (IL)
  • Ochsner Health System (US)
  • Endocrinology Research Center (RU)
  • Singleton Hospital (GB)
  • Novo Nordisk (Denmark) (DK)
  • Oslo University Hospital (NO)
Corresponding author
Meneghini, Luigi
Venue
Diabetes Care
Published
2013-03-14
Volume
36
Issue
4
Pages
858-864
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2146026006
Cited by
226
References
26
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 10 · 2020: 11 · 2019: 20 · 2018: 31 · 2017: 21 · 2016: 29 · 2015: 27 · 2014: 34 · 2013: 22
FWCI
29.43
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
insulin degludec, insulin glargine, basal insulin analogues, type 2 diabetes, injection timing, glycemic control, HbA1c, hypoglycemia, non-inferiority
MeSH terms
Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.